* If you want to update the article please login/register
Ceftriaxone in mice was investigated by aerosol inhalation. Staphylococcus autus, 25 953, and Klebsiella pneumoniae 82 in mice was investigated for mice infected with Klebsiella pneumoniae 82 and Staphylococcus aureus ATCC 25 953. The high antibacterial effectiveness of this type of treatment was shown by the survival rate for infected mice after ceftriaxone aerosol therapy.
Source link: https://doi.org/10.3390/antibiotics11101305
For the first treatment of community-acquired pneumonia, the use of ceftriaxone and sulbactam-ampicillin is recommended by the new guidelines. Hence, this systematic review and meta-analysis seeks to determine the effectiveness of ceftriaxone and sulbactam-ampicillin in the initial therapy of CAP. The initial antibiotic therapy for CAP included patients treated with ceftriaxone or sulbactam-ampicillin, according to the reports. The mortality and surgical cure rates were analyzed. The pooled analysis showed that no significant differences in the mortality and clinical cure rates among patients treated with ceftriaxone and those treated with sulbactam-ampicillin were present in the mortality and clinical cure rates.
Source link: https://doi.org/10.3390/antibiotics11101291
Salmonella enterica serovar Kentucky is an emerging human pathogen in industrialized nations and a concern for public health in developing countries. Although genus Salmonella is usually susceptible to several antimicrobial agents, a recent rise in resistance has been a point of worry. This is the first case report of Salmonella enterica serovar Kentucky, which is resistant to ceftriaxone. Salmonella Kentucky multidrug resistance patterns are present throughout the world.
Source link: https://doi.org/10.1055/s-0042-1757414
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions